Back
Science

Study Links Hormonal Birth Control and Menopause Therapy to Brain Health in Older Women

Generated on: Last updated: 1 sources
View source

Study Links Estrogen-Based Therapies to Larger Brain Volumes in Older Women

Key Finding: Women who used estrogen-based hormone therapies—including birth control in young adulthood and menopausal hormone therapy (MHT)—showed larger brain volumes in regions critical for memory and cognition, according to new research from the University of Kansas.

The Study

Researchers examined 459 women aged 65–80, analyzing three types of hormone exposure: hormonal birth control, menopausal hormone therapy (MHT) , and natural hormone exposure (estimated by age at menopause). The findings were published in NeuroImage.

Key Findings

  • Women who used estrogen-based therapies (birth control or MHT) had larger brain volumes in regions vital for memory and information processing.
  • Later menopause (indicating longer natural hormone exposure) was associated with a thicker cortex in brain regions vulnerable to Alzheimer's disease.
  • The evidence suggests that lifetime accumulation of estrogen exposure may be beneficial for brain health.

Why This Matters

About two-thirds of Alzheimer's disease patients are women, making the role of hormones a critical area of investigation.

Co-lead author Amber Watts explained: "It's showing a protective effect — using estrogen-based hormone therapies was beneficial for the brain in older women."

Importantly, the study examined hormone exposure across early adulthood and midlife, not just the menopausal transition.

Watts added: "Estrogen is neuroprotective... beneficial for white matter integrity, helps protect neurons, and is important for vascular function."

Context

A 2002 Women's Health Initiative study raised concerns about hormone therapy, but subsequent research has revised those conclusions. Previous work by Watts (2022) also found associations between birth control, hormone therapy, and cognitive outcomes.

Study Details

  • Participants: 459 women, ages 65–80
  • Exposure types examined: Hormonal birth control, menopausal hormone therapy, and natural hormone exposure
  • Co-authors: Researchers from University of Kansas Alzheimer's Disease Research Center, University of Pittsburgh, AdventHealth Research Institute, and others